Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
Braveheart Bio cash
Cash and short-term investments held at the end of each period.
Braveheart Bio's cash was $503.50M at Sep 30, 2026. For fiscal 2025 it was $89.16M.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.16M | – |
| FY2024 | Dec 31, 2024 | $0 | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $503.50M | +25174900.0% |
| Q2 FY2026 | Jun 30, 2026 | $122.83M | – |
| Q4 FY2025 | Dec 31, 2025 | $89.16M | – |
| Q3 FY2025 | Sep 30, 2025 | $67.53M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
See a number that looks wrong?